Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer.
暂无分享,去创建一个
[1] N. Park,et al. Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. , 2001, Cancer letters.
[2] A. Scorilas,et al. Codon 89 polymorphism in the human 5 α -reductase gene in primary breast cancer , 2001, British Journal of Cancer.
[3] L. Hutchins,et al. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. , 2000, Cancer research.
[4] Stephen M. Mount,et al. Genomic sequence, splicing, and gene annotation. , 2000, American journal of human genetics.
[5] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[6] B. Wasylyk,et al. Association between polymorphism in p21(Waf1/Cip1) cyclin-dependent kinase inhibitor gene and human oral cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[7] B. Weber,et al. Low penetrance genes associated with increased risk for breast cancer. , 2000, European journal of cancer.
[8] B. Iacopetta,et al. Routine analysis of p53 mutation in clinical breast tumor specimens using fluorescence-based polymerase chain reaction and single strand conformation polymorphism. , 2000, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[9] B. Weber,et al. Assessing the risk of breast cancer. , 2000, The New England journal of medicine.
[10] B. Ponder,et al. A Systematic Review Of Genetic Polymorphisms and Breast Cancer Risk 1 , 2000 .
[11] N. Roodi,et al. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. , 1998, Cancer research.
[12] T. Rebbeck,et al. p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. , 1998, Anticancer research.
[13] K. Horwitz,et al. Progesterone Regulates Transcription of the p21 WAF1 Cyclindependent Kinase Inhibitor Gene through Sp1 and CBP/p300* , 1998, The Journal of Biological Chemistry.
[14] I. Campbell,et al. TP53 intron 6 polymorphism and the risk of ovarian and breast cancer. , 1998, British Journal of Cancer.
[15] B. Iacopetta,et al. Detection of p53 gene mutation by rapid PCR‐SSCP and its association with poor survival in breast cancer , 1997, International journal of cancer.
[16] K. Horwitz,et al. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). , 1997, Molecular endocrinology.
[17] S. Sukumar,et al. Altered WAF1 genes do not play a role in abnormal cell cycle regulation in breast cancers lacking p53 mutations. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] M. Becich,et al. Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin‐dependent kinase inhibitor gene , 1997, Cancer.
[19] N. Day,et al. Family history and the risk of breast cancer: A systematic review and meta‐analysis , 1997, International journal of cancer.
[20] S. Avigad,et al. A novel germ line p53 mutation in intron 6 in diverse childhood malignancies , 1997, Oncogene.
[21] I. Bleiweiss,et al. p53 haplotype determination in breast cancer. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[22] W. Foulkes,et al. Polymorphisms in P21CIP1/WAF1 are not correlated with TP53 status in sporadic ovarian tumours. , 1996, European journal of cancer.
[23] S. Al-Sedairy,et al. Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas. , 1996, British Journal of Cancer.
[24] X. Montano,et al. Analysis of intron 4 of the p53 gene in human cutaneous melanoma. , 1996, Gene.
[25] R. Birgander,et al. Association between the p21 codon 31 A1 (arg) allele and lung cancer. , 1996, Human heredity.
[26] G. Hallmans,et al. p53 polymorphisms and haplotypes in breast cancer. , 1996, Carcinogenesis.
[27] D. Eccles,et al. p53 polymorphism in ovarian and breast cancer , 1996, The Lancet.
[28] V. Rotter,et al. A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. , 1995, DNA and cell biology.
[29] J. Lancaster,et al. p53 polymorphism in ovarian and bladder cancer , 1995, The Lancet.
[30] P. D. Lee,et al. Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. , 1995, Human Molecular Genetics.
[31] R. Kreienberg,et al. p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer , 1995, The Lancet.
[32] L. Poston,et al. Insulin resistance and membrane abnormalities , 1995, The Lancet.
[33] B. Vogelstein,et al. Absence of WAF1 mutations in a variety of human malignancies. , 1994, Blood.
[34] D. Givol,et al. A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. , 1994, Oncogene.
[35] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.
[36] V. Lazar,et al. Simple sequence repeat polymorphism within the p53 gene. , 1993, Oncogene.
[37] D. Lane,et al. p53, guardian of the genome , 1992, Nature.
[38] S. Pacini,et al. Vitamin D receptor gene polymorphism is associated with metastatic breast cancer. , 1998, Oncology research.
[39] S. Groshen,et al. WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. , 1997, The American journal of pathology.
[40] A. Marchetti,et al. Absence of somatic mutations in the coding region of the waf1/cip1 gene in human breast, lung and ovarian carcinomas - a polymorphism at codon-31. , 1995, International journal of oncology.